The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | Evolving treatment options in NDMM: transplant-eligible and transplant-ineligible patients
In this video, Leo Rasche, MD, University of Würzburg, Würzburg, Germany, gives an overview of his presentation at this year’s meeting, which focused on the evolving treatment landscape in newly diagnosed multiple myeloma (NDMM). Dr Rasche highlights the complexity of myeloma treatment, and further discusses the current standard of care (SOC) in patients with transplant-eligible and transplant-ineligible disease in the frontline setting. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
